Wall Street analysts forecast that AngioDynamics, Inc. (NASDAQ:ANGO) will post earnings of $0.02 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for AngioDynamics’ earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.02. AngioDynamics posted earnings per share of $0.22 during the same quarter last year, which indicates a negative year-over-year growth rate of 90.9%. The business is expected to report its next quarterly earnings report on Friday, January 3rd.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
On average, analysts expect that AngioDynamics will report full year earnings of $0.12 per share for the current fiscal year. For the next financial year, analysts anticipate that the firm will post earnings of $0.30 per share, with EPS estimates ranging from $0.29 to $0.30. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.04. The company had revenue of $66.00 million during the quarter, compared to the consensus estimate of $67.74 million. AngioDynamics had a return on equity of 4.89% and a net margin of 17.79%. AngioDynamics’s revenue was up 3.3% on a year-over-year basis. During the same period last year, the business posted $0.16 earnings per share.
Several research firms recently issued reports on ANGO. BidaskClub lowered AngioDynamics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 8th. KeyCorp dropped their price objective on AngioDynamics from $30.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 4th. ValuEngine raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, TheStreet downgraded AngioDynamics from a “c” rating to a “d+” rating in a research report on Thursday, October 3rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $21.33.
Shares of ANGO traded up $0.08 on Friday, reaching $15.09. 228,900 shares of the company’s stock traded hands, compared to its average volume of 235,403. The stock has a market cap of $568.81 million, a PE ratio of 18.18 and a beta of 0.63. AngioDynamics has a 52-week low of $13.72 and a 52-week high of $25.48. The stock’s 50 day simple moving average is $15.76 and its two-hundred day simple moving average is $18.69.
In other news, CEO James C. Clemmer purchased 15,000 shares of the stock in a transaction on Friday, October 25th. The shares were acquired at an average price of $14.19 per share, for a total transaction of $212,850.00. Following the completion of the transaction, the chief executive officer now directly owns 260,418 shares of the company’s stock, valued at approximately $3,695,331.42. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 3.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in AngioDynamics by 0.6% during the second quarter. BlackRock Inc. now owns 5,860,071 shares of the medical instruments supplier’s stock valued at $115,384,000 after purchasing an additional 36,718 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of AngioDynamics by 40.5% in the second quarter. Victory Capital Management Inc. now owns 3,773,543 shares of the medical instruments supplier’s stock worth $74,301,000 after buying an additional 1,086,847 shares during the period. Northern Trust Corp increased its holdings in shares of AngioDynamics by 1.0% in the second quarter. Northern Trust Corp now owns 1,179,665 shares of the medical instruments supplier’s stock worth $23,228,000 after buying an additional 11,387 shares during the period. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of AngioDynamics by 0.8% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 651,319 shares of the medical instruments supplier’s stock worth $12,824,000 after buying an additional 5,000 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of AngioDynamics by 27.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 607,751 shares of the medical instruments supplier’s stock worth $11,967,000 after buying an additional 129,497 shares during the period. Institutional investors and hedge funds own 98.79% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Article: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com